The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of Alkagin Paste compared to patients treated with institutional standard skin care.

Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment

Other: Aveeno cream

Apply cream on irradiated area twice a day

Experimental: Arm B: standard of care plus Alkagin paste

Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.

Other: Aveeno cream

Apply cream on irradiated area twice a day

Other: Alkagin paste

Apply Alkagin paste three times a day.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients receiving a dose of 45 Gy or more with concomitant chemotherapy to the perineal skin (for treatment of anal canal, low rectal or gynecological cancer).

Patients able to understand and sign an informed consent form.

Patients that do not have active connective tissue disorders.

Patients 18 years or older.

Patients that did not receive any previous radiation.

Patients that do not have any known allergy to any ingredients of the Alkagin Paste

Patients need to be able to apply the creams themselves or have help with applying the creams.

Patients who have been offered to purchase silver clear underpants but have refused

Exclusion Criteria:

Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01408407